Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADHERE open-label extension in CIDP
2019-003107-35Phase 2Active
- Sponsor
- argenx
- Start
- Feb 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoint: Incidence of TEAEs and SAEs by system organ class and preferred term. Started Feb 2020; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2019-003107-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003107-35.